Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Coherus Bio (CHRS)

Coherus Bio (CHRS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 169,363
  • Shares Outstanding, K 115,213
  • Annual Sales, $ 257,240 K
  • Annual Income, $ -237,890 K
  • EBIT $ -138 M
  • EBITDA $ -135 M
  • 60-Month Beta 0.86
  • Price/Sales 0.64
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 100.92% ( -17.11%)
  • Historical Volatility 138.28%
  • IV Percentile 35%
  • IV Rank 16.88%
  • IV High 567.48% on 06/05/24
  • IV Low 6.15% on 08/15/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 139
  • Volume Avg (30-Day) 3,246
  • Put/Call OI Ratio 0.01
  • Today's Open Interest 75,422
  • Open Int (30-Day) 79,684

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.29
  • Number of Estimates 3
  • High Estimate -0.21
  • Low Estimate -0.33
  • Prior Year -0.72
  • Growth Rate Est. (year over year) +59.72%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.1200 +31.25%
on 11/25/24
2.4300 -39.51%
on 12/03/24
+0.3800 (+34.86%)
since 11/22/24
3-Month
0.6603 +122.63%
on 11/05/24
2.4300 -39.51%
on 12/03/24
+0.4700 (+47.00%)
since 09/24/24
52-Week
0.6603 +122.63%
on 11/05/24
3.7000 -60.27%
on 01/02/24
-0.5500 (-27.23%)
since 12/22/23

Most Recent Stories

More News
Coherus BioSciences Initiates Phase 2 Study of Casdozokitug Combined with Toripalimab and Bevacizumab for Liver Cancer Treatment

Coherus BioSciences initiates a Phase 2 study evaluating casdozokitug, toripalimab, and bevacizumab for liver cancer treatment.Quiver AI SummaryCoherus BioSciences has launched a randomized Phase 2 study...

CHRS : 1.4700 (+2.80%)
Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025

CHRS : 1.4700 (+2.80%)
Coherus Announces Agreement to Divest UDENYCA® Franchise for up to $558 million to Intas Pharmaceuticals Ltd.

CHRS : 1.4700 (+2.80%)
Coherus Management to Participate in the 2024 Citi Global Healthcare Conference

CHRS : 1.4700 (+2.80%)
Coherus BioSciences: Q3 Earnings Snapshot

Coherus BioSciences: Q3 Earnings Snapshot

CHRS : 1.4700 (+2.80%)
Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update

CHRS : 1.4700 (+2.80%)
Coherus to Report Third Quarter 2024 Financial Results on November 6, 2024

CHRS : 1.4700 (+2.80%)
Coherus BioSciences: Q2 Earnings Snapshot

Coherus BioSciences: Q2 Earnings Snapshot

CHRS : 1.4700 (+2.80%)
Coherus BioSciences: Q1 Earnings Snapshot

Coherus BioSciences: Q1 Earnings Snapshot

CHRS : 1.4700 (+2.80%)
Why Coherus Biosciences Stock Tumbled on Thursday

The company fell well short of expectations for its fourth quarter.

CHRS : 1.4700 (+2.80%)

Business Summary

Coherus Biosciences, Inc. is a biologics platform company developing biosimilar therapeutics. Its clinical stage pipeline consists of CHS-0214 in two Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis; CHS-1420 that has completed a Phase I study to treat psoriasis or rheumatoid...

See More

Key Turning Points

3rd Resistance Point 1.6467
2nd Resistance Point 1.5633
1st Resistance Point 1.5167
Last Price 1.4700
1st Support Level 1.3867
2nd Support Level 1.3033
3rd Support Level 1.2567

See More

52-Week High 3.7000
Fibonacci 61.8% 2.5388
Fibonacci 50% 2.1802
Fibonacci 38.2% 1.8215
Last Price 1.4700
52-Week Low 0.6603

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar